Tag: GlobeNewswire

Custom vehicles and Gentex tech for automotive OEMs, accessory programs, and the aftermarket

LAS VEGAS, Nov. 03, 2026 (GLOBE NEWSWIRE) — The latest Gentex Corporation (NASDAQ: GNTX) technology for automotive OEMs, accessory programs, and the aftermarket will be on display in the company’s booth at the SEMA show kicking off today in Las Vegas. In addition, Gentex tech will feature prominently on two custom car unveils: one from the world-renowned Ringbrothers, and another from the elite restoration shop, Classic Car Studio.

Gentex is a long-time supplier of electro-optical products for the global automotive, aerospace, fire protection, and consumer electronics industries. It’s best known for supplying nearly every major automaker with connected-car technologies and advanced electronic features that optimize driver vision and enhance safety.

“The aftermarket has always been a source of innovation for Gentex and the automotive industry in general,” said Gentex Chief Technology Officer and Chief Operations Officer Neil Boehm. “Many of the trends and technologies that begin with car enthusiasts ultimately influence the broader market. SEMA keeps us connected to car culture, allowing us to converse with the forward-thinking builders, suppliers, and industry leaders shaping the future of mobility and vehicle customization.”

Gentex’s SEMA booth will feature a wide variety of products, including automatic-dimming mirrors, digital rearview mirrors, the HomeLink car-to-home automation system, and dimmable sun visors. The company will also showcase its GNTX-R mirror, a slim profile, carbon fiber, automatic-dimming rearview mirror designed specifically for the custom car market and sold through Ringbrothers. Its unique design was specifically engineered for custom car builds, supercars, tuners, imports, drift cars, and prototypes.

The Gentex GNTX-R mirror is available in either red or black and incorporates frameless, chrome-ring glass with a carbon fiber substructure to create a sleek, modern look. It’s also electrochromic, with integrated sensors, microprocessor, and proprietary darkening gel that work together to detect and eliminate dangerous rearview mirror glare. The product is available from the Ringbrothers’ online parts store.

Ringbrothers will also debut a vehicle at the Gentex booth — a 1965 Pontiac GTO convertible called Billie. Gary Ragle of Ragle Design once again spearheaded the vehicle’s design, widening the fenders and doors 2.5 inches on either side to broaden the vehicle’s stance. The body sits on a Roadster Shop chassis and suspension with reimagined carbon fiber hood, door skins, front valance and more. The fully bespoke interior features Gentex’s GNTX-R auto-dimming mirror.

In addition to the Ringbrothers unveil, the Gentex booth will feature the debut of Brownfinger, a custom 1970 Plymouth ‘Cuda built by Classic Car Studio. Headquartered in St Louis, MO, Classic Car Studio is recognized for its custom classic cars and trucks, from meticulously crafted restorations to jaw-dropping custom builds.

Brownfinger sits atop a Roadster Shop FAST TRACK chassis with a DSR Performance 7.0L Hemi V8 that generates 1,200 HP. The vehicle’s aggressive stance is further enhanced by a deep, rich, golden-bronze paint job that is sure to turn heads. The vehicle is equipped with a Gentex Full Display Mirror, automatic-dimming exterior mirrors, and dimmable sun visors.

The two vehicle unveils will be hosted by professional emcee, host and presenter Jarod DeAnda, and will take place in succession beginning at 10:30 a.m. today at the Gentex booth.

The Specialty Equipment Market Association (SEMA) show is the world’s premier automotive specialty products trade event. This year’s show takes place November 3-6 at the Las Vegas Convention Center in Las Vegas, Nevada. Gentex’s display can be seen in Central Hall, Hot Rod Alley, booth 23889. 

VOXX by Gentex, a Gentex subsidiary and leading provider of aftermarket electronics, vehicle security, and mobile entertainment solutions, will also be at SEMA in the North Hall, booth 10809.

Founded in 1974, Gentex Corporation (NASDAQ: GNTX) is a technology company that leverages its core competencies, strategic partnerships, acquisitions, and ongoing research to create market-leading positions in a variety of verticals. You can view some of the Company’s latest technology at www.gentex.com.

Gentex Media Contact
Craig Piersma
(616) 747-9821
craig.piersma@gentex.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9312c2f7-5dc1-4c0f-80b3-debb0bbef7eb
https://www.globenewswire.com/NewsRoom/AttachmentNg/457fba3b-9980-4c70-a59f-1eb6c261abd9

ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2026 financial results will be released before market open on Tuesday, November 10, 2026. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Tuesday, November 10, 2026 to discuss the results and recent operational highlights.

To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance of the conference call. The live webcast can be accessed under “Events & Presentations” in the Investor Relations section of the company’s website at https://ir.lensar.com. Following the live webcast, an archived version of the call will be available on the website.

About LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System^® as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline^® software technology, designed to guide surgeons to achieve better outcomes.

Contacts:		Lee Roth
Mike Rossi, Interim CFO		Burns McClellan for LENSAR
ir.contact@lensar.com		lroth@burnsmc.com

EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December:

• Guggenheim 3^rd Annual Healthcare Innovation Conference: Tuesday, November 10, 2026; Fireside chat at 4:30 p.m. ET
• Stifel 2026 Healthcare Conference: Wednesday, November 11, 2026; Fireside chat at 8:00 a.m. ET
• Jefferies Global Healthcare Conference in London: Monday, November 16, 2026; Fireside chat at 1:30 p.m. GMT
• 9^th Annual Evercore Healthcare Conference: Tuesday, December 1, 2026; Fireside chat at 8:45 a.m. ET
• Citi Global Healthcare Conference 2026: Wednesday, December 2, 2026; Fireside chat at 3:00 p.m. ET
• Piper Sandler 38^th Annual Healthcare Conference: Thursday, December 3, 2026; Fireside chat at 8:30 a.m. ET
• Barclays Virtual Ophthalmology Day: Thursday, December 10, 2026; Fireside chat at 10:30 a.m. ET

Archived copies of the webcasts will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT  

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate, 4D-150, is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration and the second indication is diabetic macular edema, which are both in Phase 3 development. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.  

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.  

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Jenn Gordon
dna Communications
Media@4DMT.com

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com

REDWOOD CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”), a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies, today announced participation in two upcoming investor conferences. 

Sheila Gujrathi, M.D., Chief Strategy Officer of Bolt and Co-Founder and former Chief Executive Officer of Prana Therapies, will deliver a company presentation, followed by a fireside chat, on Tuesday, November 10, 2026, at 10:40 a.m. ET at the Stifel 2026 Healthcare Conference, and attend Jefferies Global Healthcare Conference in London, taking place November 16–19, 2026.

In October 2026, Bolt acquired Prana Therapies in a stock-for-stock reverse merger alongside a $120 million private placement financing, with the potential for up to an additional $60 million upon exercise of accompanying warrants. Following the acquisition, Bolt is primarily focused on advancing Prana’s pipeline of next-generation, half-life-extended multispecific antibodies, led by PRA-216, which is currently in Phase 2 development across multiple inflammatory diseases.

Members of the management team will host one-on-one investor meetings during the conferences. A live webcast of the Stifel presentation will be available on the Events and Presentations section of Bolt’s website at https://investors.boltbio.com/news-and-events/events-and-presentations, with an archived replay accessible following the event date.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics is a clinical-stage biotechnology company pioneering a new generation of half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Through the proprietary INSPIRE platform it acquired from Prana Therapies, the company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for differentiated efficacy, extended exposure, and convenient dosing.

The company’s lead program, PRA-216, is a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase 2 study planned in eosinophilic esophagitis. In addition to PRA-216, Bolt Biotherapeutics is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need.

Bolt’s pipeline also includes BDC-4182, a claudin 18.2-targeting Boltbody™ ISAC.

For more information, please visit https://www.boltbio.com/.

Forward-Looking Statements

This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including, without limitation, statements regarding Bolt, Prana, the concurrent private placement financing and the acquisition of Prana by Bolt (the “Transactions”) and other matters, including, without limitation, statements regarding: any additional gross proceeds that may be received upon exercise, if any, of accompanying warrants, if any, in the Transactions and the expected effects, perceived benefits or opportunities and related timing with respect thereto; expectations regarding or plans for the company’s pipeline, including its ongoing and planned clinical trials, research and development programs and the expected timing for key milestones, including the release of clinical data; the potential benefits of PRA-216 and Prana’s other clinical programs; and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the company’s ability to consummate the private placement financing or realize the anticipated benefits from the transactions, including as a result of its failure to receive the requisite stockholder approvals; investors in the private placement may not exercise their warrants and the company may not receive any additional proceeds therefrom; the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.

Contacts

Christina Trout
VP, Corporate Development
investors@pranatherapies.com
(650) 665-9295

Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com

PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences:

• Guggenheim’s 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
• 2026 Jefferies Global Healthcare Conference in London: Meetings with investors and a webcasted fireside chat at 5:00 p.m. GMT (12:00 p.m. ET) on Wednesday, November 18, 2026, in London, UK.

The webcasted fireside chats will be accessible on the News and Events section of the Company’s website at www.cabalettabio.com. Archived replays will be available for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, rese-cel, is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.

Contacts
Investors: investors@cabalettabio.com
Media: media@cabalettabio.com

– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.

– Two additional presentations to cover first-in-human Phase 2a study design and preclinical results for Humacyte’s investigational coronary tissue engineered vessel.

DURHAM, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at a commercial scale, announced today that the Company’s regenerative medicine technology will be highlighted in three presentations at the American Heart Association (AHA) Scientific Sessions 2026. The conference will be taking place from November 6–9th at McCormick Place Convention Center in Chicago, Illinois.

AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists. Humacyte’s presentations include an invited talk by the company’s Founder, President and Chief Executive Officer, Laura Niklason, M.D., Ph.D., and two presentations highlighting Humacyte’s investigational coronary tissue engineered vessel (CTEV), a small-diameter bioengineered vessel for coronary artery bypass grafting (CABG).

“AHA brings together the cardiac surgeons and cardiologists who will ultimately decide whether an off-the-shelf conduit belongs in bypass surgery, and we are excited for them to see our preclinical data and our study design firsthand,” said Dr. Niklason. “Our approach is built on the idea that the body can repopulate an engineered vessel with a patient’s own cells. With the CTEV, we are taking the next step toward bringing bioengineered vascular technology to coronary bypass surgery through the first U.S. clinical trial of a bioengineered CABG conduit.”

Presentation details:

Invited Talk

• Title: Engineering the Microenvironment to Accelerate Vascular Regeneration
• Presenter: Laura E. Niklason, M.D., Ph.D., Founder and CEO, Humacyte, Inc.
• Date and time: Saturday, November 7, 2026, 10:15 AM CT
• Location: North Hall, Level 3, McCormick Place, Chicago

Clinical Study Design

• Title: First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting
• Presenters: John Alexander, M.D., M.H.S., Professor of Medicine/Cardiology, Duke Clinical Research Institute at Duke University and Alan Kypson, M.D., Cardiothoracic Surgeon, UNC Rex Hospital
• Date and time: Saturday, November 7, 2026, 3:57 PM CT
• Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 1, McCormick Place, Chicago

Preclinical CABG Results

• Title: Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting
• Presenter: Robert Kirkton, Ph.D., Executive Director of New Product and Process Development, Humacyte, Inc.
• Date and time: Sunday, November 8, 2026, 9:15 AM CT
• Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 2, McCormick Place, Chicago

The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat and be available for one-on-one meetings at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:00 p.m. ET in New York, NY.

A live and archived audio webcast of the fireside chat will be available through the Investor section of Geron’s website at www.geron.com.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO^® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.

Stifel 2026 Healthcare Conference
Fireside Chat: Tuesday, November 10, 2026, at 10:00 a.m. ET
Location: New York, New York

Jefferies Global Healthcare Conference in London
Presentation: Monday, November 16, 2026, at 1:00 p.m. GMT
Location: London, England

Live webcasts of the fireside chat and presentation will be available on the “News & Events” page within the Investors section of the City Therapeutics’ website at investors.citytx.com. A replay of the webcasts will be available for approximately 90 days.

About City Therapeutics
City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City’s lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection. For more information, visit www.citytx.com and follow us on LinkedIn, X, and Bluesky.

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

Investor Contact: 
Stephanie Ascher, Precision AQ
Stephanie.Ascher@precisionaq.com

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2026 and will also participate in one-on-one investor meetings at each of these conferences.

Guggenheim 3^rd Annual Healthcare Innovation Conference
Location: InterContinental Boston, Boston, MA
Format: Fireside Chat
Date and Time: Tuesday, November 10, 3:30 pm Eastern Time

Stifel 2026 Healthcare Conference
Location: Lotte New York Palace, New York, NY
Format: Fireside Chat
Date and Time: Wednesday, November 11, 9:20 am Eastern Time

Jefferies Global Healthcare Conference
Location: The Waldorf Hilton, London, UK
Format: Fireside Chat
Date and Time: Wednesday, November 18, 12:30 pm Greenwich Mean Time

A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

• Potential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed

A Media Snippet accompanying this announcement is available by clicking on this link.

FLORHAM PARK, N.J, Nov. 03, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible commercially insured patients may pay as little as $0 for VOQUEZNA^® (vonoprazan) tablets exclusively through BlinkRx, Phathom’s pharmacy network partner, subject to eligibility requirements, benefit limits, and program terms. The offer is part of Phathom’s broader efforts to make it easier and more affordable for patients with gastroesophageal reflux disease (GERD) to fill their VOQUEZNA prescriptions.

“We believe that patients with GERD who are prescribed VOQUEZNA should be able to start and stay on their medication, without unnecessary cost or paperwork getting in the way,” said Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals. “By partnering with BlinkRx, we’re working to make VOQUEZNA easier and more affordable to access, with eligible commercially insured patients now having the potential to pay as little as $0, as well as continuing to offer a cash-pay option for those without insurance coverage. For many people living with GERD, finding the right treatment can be a long journey. Once their doctor prescribes VOQUEZNA, starting treatment should be the easy part. This initiative reflects our focus on putting patients first.”

How it works

• As little as $0: Commercially insured patients may pay as little as $0 for VOQUEZNA exclusively through BlinkRx, subject to eligibility requirements, benefit limits, and terms and conditions, whether their prescription is for a 30-, 60- or 90-day supply of VOQUEZNA 10 mg or 20 mg tablets.
• Lowest eligible cost, automatically: BlinkRx automatically identifies the lowest out-of-pocket cost available through its program, including the $0 offer when available for eligible patients, with no coupon or copay card to keep track of.
• Free home delivery and easy refills: VOQUEZNA ships directly to the patient’s door at no extra cost, and patients can schedule and receive refills without a trip to the pharmacy.
• Help with insurance requirements: BlinkRx coordinates directly with doctors’ offices on prior authorization and other insurance requirements, when needed, to help simplify the prescription process.

How to get started
Patients can ask their healthcare provider to send their prescription for VOQUEZNA tablets directly to BlinkRx U.S., Boise, Idaho. Once BlinkRx receives the prescription, patients will be sent a secure link by text or email to set up their BlinkRx patient profile and complete their order. Learn more at www.VOQUEZNA.com/cost-and-savings.

Who’s eligible for the $0 offer?
The $0 offer applies to VOQUEZNA tablets and is available to patients 18 years of age or older whose commercial insurance covers VOQUEZNA subject to eligibility requirements, benefit limits, and terms and conditions. The $0 offer is not available to patients whose prescriptions are paid for by a government health program as federal law prohibits Phathom from providing copay savings offers to such patients. The $0 offer is not available to Massachusetts residents, as state law does not permit manufacturer copay assistance that excludes or favors any pharmacy. Eligible commercially insured Massachusetts residents may pay as little as $25 for a 30-day supply, $50 for a 60-day supply, or $90 for a 90-day supply of VOQUEZNA with the VOQUEZNA Savings Card at BlinkRx or participating retail pharmacies.

Additional ways to save on VOQUEZNA
Retail pharmacies: Eligible patients with commercial insurance who prefer a retail pharmacy can continue to use the VOQUEZNA Savings Card and may pay as little as $25 for a 30-day supply, subject to eligibility requirements, benefit limits, and terms and conditions.

Cash-pay option: Eligible patients without insurance or whose insurance does not cover VOQUEZNA may pay as little as $55 for a 30-day supply through BlinkRx. This cash-pay option is only available through BlinkRx.

Phathom reserves the right to change or discontinue these offers at any time without notice. See full terms and learn more at www.VOQUEZNA.com/cost-and-savings.

About VOQUEZNA^® (vonoprazan)
VOQUEZNA^® (vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, the relief of heartburn associated with Erosive GERD, and the relief of heartburn associated with Non-Erosive GERD. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and numerous other countries in Asia and Latin America.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is VOQUEZNA?

• VOQUEZNA^® (vonoprazan) is a prescription medicine used in adults:
  • for 8 weeks to heal acid-related damage to the lining of the esophagus (called Erosive Esophagitis) and for relief of heartburn related to Erosive Esophagitis.
  • for up to 6 months to maintain healing of Erosive Esophagitis and for relief of heartburn related to Erosive Esophagitis.
  • for 4 weeks for relief of heartburn related to gastroesophageal reflux disease (GERD).

It is not known if VOQUEZNA is safe and effective in children.

Do not take VOQUEZNA if you:

• are allergic to vonoprazan or any of the other ingredients in VOQUEZNA. Allergic reaction symptoms may include trouble breathing, rash, itching, and swelling of your face, lips, tongue or throat.
• are taking a medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY) used to treat HIV-1 (Human Immunodeficiency Virus).

Before taking VOQUEZNA, tell your healthcare provider about all your medical conditions, including if you:

• have low magnesium, calcium, or potassium in your blood, or you are taking a medicine to increase urine (diuretic).
• have kidney or liver problems.
• are pregnant, think you may be pregnant, or plan to become pregnant. It is not known if VOQUEZNA will harm your unborn baby.
  • Pregnancy Exposure Registry: There is a pregnancy registry for women who take VOQUEZNA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with VOQUEZNA, talk to your healthcare provider about how you can join this pregnancy registry or you can enroll in the registry by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/.
• are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take VOQUEZNA while breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

VOQUEZNA may affect how other medicines work, and other medicines may affect how VOQUEZNA works. Especially tell your healthcare provider if you take medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY).

What are the possible side effects of VOQUEZNA?

VOQUEZNA may cause serious side effects including:

• A type of kidney problem (acute tubulointerstitial nephritis): Some people who take VOQUEZNA may develop a kidney problem called acute tubulointerstitial nephritis. Call your healthcare provider right away if you have a decrease in the amount that you urinate or if you notice blood in your urine.
• Diarrhea caused by an infection (Clostridioides difficile) in your intestines: Call your healthcare provider right away if you have watery stools, stomach pain, and fever that does not go away.
• Bone fractures (hip, wrist, or spine): Bone fractures in the hip, wrist, or spine may happen in people who take multiple daily doses of another type of medicine that reduces acid in your stomach known as proton pump inhibitors (PPI medicines) for a long period of time (a year or longer). Tell your healthcare provider if you have a bone fracture, especially in the hip, wrist, or spine.
• Severe skin reactions: VOQUEZNA can cause rare, but severe skin reactions that may affect any part of your body. These serious skin reactions may need to be treated in a hospital and may be life threatening:
  • Skin rash which may have blistering, peeling, or bleeding on any part of your skin.
  • You may also have fever, chills, body aches, shortness of breath, or enlarged lymph nodes.

   If you experience any of these symptoms, stop taking VOQUEZNA and call your healthcare provider right away. These symptoms may be the first sign of a severe skin reaction.

• Low vitamin B-12 levels: VOQUEZNA lowers the amount of acid in your stomach. Stomach acid is needed to absorb Vitamin B12 properly. Tell your healthcare provider if you have symptoms of low vitamin B12 levels, including irregular heartbeat, shortness of breath, lightheadedness, tingling or numbness in the arms or legs, muscle weakness, pale skin, feeling tired, or mood changes. Talk with your healthcare provider about the risk of low vitamin B12 levels if you have been on VOQUEZNA for a long time.
• Low magnesium levels in the body can happen in people who take VOQUEZNA. Tell your healthcare provider right away if you have symptoms of low magnesium levels, including seizures, dizziness, irregular heartbeat, jitteriness, muscle aches or weakness, or spasms of the hands, feet, or voice.
• Stomach growths (fundic gland polyps): A certain type of stomach growth called fundic gland polyps may happen in people who take another type of medicine that reduces acid in your stomach known as proton pump inhibitors (PPI medicines) for a long time. Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

The most common side effects of VOQUEZNA for treatment of Erosive Esophagitis or relief of heartburn related to gastroesophageal reflux disease include:

• stomach inflammation
• diarrhea
• stomach bloating
• stomach pain
• nausea
• indigestion
• constipation
• high blood pressure
• urinary tract infection

These are not all the possible side effects of VOQUEZNA. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Patient Information and full Prescribing Information for VOQUEZNA.

About Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus. An estimated 15 million U.S. adults are treated for GERD with a prescription medication. GERD has two main forms. Non-Erosive GERD, the most common form, causes symptoms such as frequent heartburn, regurgitation, difficulty swallowing and chest pain without visible damage to the esophagus. Erosive GERD, also called Erosive Esophagitis, involves erosions in the lining of the esophagus caused by stomach acid and, when inadequately treated, can progress to more serious conditions, including Barrett’s esophagus and esophageal cancer.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding our patient access initiatives and the anticipated benefits of our programs with BlinkRx, including the potential to improve the affordability and accessibility of VOQUEZNA and facilitate the ability of patients to obtain and continue treatment. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risk that: changes in insurance coverage or reimbursement policies could limit patients’ ability to access VOQUEZNA or increase their out-of-pocket costs; patients may not qualify for or fully benefit from Phathom’s patient access programs; Phathom may modify, limit or discontinue these programs; or changes in applicable laws or regulations could restrict the availability or operation of these programs. Additional risks and uncertainties related to our business are described in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. Phathom undertakes no obligation to update any forward-looking statements, except as required by law.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
IR@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

11/26 US-VPZ-26-0354